We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?
Read MoreHide Full Article
Key Takeaways
LLY's neuroscience sales rose 32% to $811 million, while immunology grew 9% to $2.6 billion in H1 2026.
Kisunla and Emgality are expected to drive neuroscience Q3 growth, though competition may temper momentum.
Taltz leads immunology, while Ebglyss, Omvoh and Olumiant could boost Q3 growth despite competition.
Eli Lilly’s (LLY - Free Report) portfolio is overwhelmingly driven by its popular GLP-1 medicines, Mounjaro and Zepbound. However, Neuroscience and immunology are emerging as additional contributors to top-line growth, though both segments remain considerably smaller than Lilly’s cardiometabolic business.
Eli Lilly’s neuroscience revenues rose 32% year over year to $811 million in the first half of 2026, while immunology revenues increased 9% to $2.6 billion. Investors will monitor both segments’ performance when LLY reports third-quarter results on Oct. 29, 2026, with particular attention to commercial progress across its established therapies and newer products.
In neuroscience, Kisunla, an anti-amyloid beta antibody for early symptomatic Alzheimer’s disease, is expected to continue witnessing rapid sales growth in the third quarter. Emgality, an anti-CGRP monoclonal antibody for migraine prevention, is likely to have remained another key contributor to the segment’s revenues. Continued uptake of these products will be important to sustaining neuroscience growth.
In immunology, Taltz, an IL-17A inhibitor, remains the largest contributor, generating $1.6 billion in first-half revenues. Meanwhile, newer products Ebglyss and Omvoh are expected to support segment growth in the third quarter as they continue to gain market share. Olumiant’s third-quarter sales momentum is expected to have been sustained by rising demand across its approved indications. In September, the FDA expanded Olumiant’s approved use to adolescents aged 12 years and older with severe alopecia areata, potentially supporting sales growth in the quarters ahead. Nevertheless, competition from established therapies could weigh on the portfolio’s growth trajectory.
LLY Faces Competition in Neuroscience and Immunology
Eli Lilly faces strong competition from Biogen (BIIB - Free Report) , Novartis (NVS - Free Report) and AbbVie (ABBV - Free Report) across its neuroscience and immunology portfolios. Biogencompetes with Lilly in Alzheimer’s disease through Leqembi, which it markets with Eisai. Like Lilly’s Kisunla, Leqembi targets amyloid beta, making BIIB/Eisai a direct competitor in the Alzheimer’s treatment market. Novartis competes with Lilly in both neuroscience and immunology. Its migraine drug Aimovig, marketed with Amgen, competes with Emgality, while Cosentyx competes with Taltz in psoriasis.
AbbVie also challenges Lilly across both therapeutic areas. Its migraine drug Qulipta competes with Emgality, while Skyrizi and Rinvoq compete with Omvoh in inflammatory bowel disease. Rinvoq also competes with Ebglyss in atopic dermatitis.
LLY’s Price Performance, Valuation and Estimates
Lilly stock has risen 19.3% so far this year compared with the industry’s growth of 17.4%. During the same period, the company has also outperformed the sector and the S&P 500, as seen in the chart below.
LLY Stock Price Movement
Image Source: Zacks Investment Research
From a valuation standpoint, LLY stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 28.63 forward earnings, higher than 19.06 for the industry. However, the stock is trading below its five-year mean of 34.60.
LLY Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share has declined from $35.88 to $33.22 over the past 60 days, while that for 2027 has risen from $45.87 to $47.23.
View the Zacks #1 Rank List
Image: Shutterstock
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?
Key Takeaways
Eli Lilly’s (LLY - Free Report) portfolio is overwhelmingly driven by its popular GLP-1 medicines, Mounjaro and Zepbound. However, Neuroscience and immunology are emerging as additional contributors to top-line growth, though both segments remain considerably smaller than Lilly’s cardiometabolic business.
Eli Lilly’s neuroscience revenues rose 32% year over year to $811 million in the first half of 2026, while immunology revenues increased 9% to $2.6 billion. Investors will monitor both segments’ performance when LLY reports third-quarter results on Oct. 29, 2026, with particular attention to commercial progress across its established therapies and newer products.
In neuroscience, Kisunla, an anti-amyloid beta antibody for early symptomatic Alzheimer’s disease, is expected to continue witnessing rapid sales growth in the third quarter. Emgality, an anti-CGRP monoclonal antibody for migraine prevention, is likely to have remained another key contributor to the segment’s revenues. Continued uptake of these products will be important to sustaining neuroscience growth.
In immunology, Taltz, an IL-17A inhibitor, remains the largest contributor, generating $1.6 billion in first-half revenues. Meanwhile, newer products Ebglyss and Omvoh are expected to support segment growth in the third quarter as they continue to gain market share. Olumiant’s third-quarter sales momentum is expected to have been sustained by rising demand across its approved indications. In September, the FDA expanded Olumiant’s approved use to adolescents aged 12 years and older with severe alopecia areata, potentially supporting sales growth in the quarters ahead. Nevertheless, competition from established therapies could weigh on the portfolio’s growth trajectory.
LLY Faces Competition in Neuroscience and Immunology
Eli Lilly faces strong competition from Biogen (BIIB - Free Report) , Novartis (NVS - Free Report) and AbbVie (ABBV - Free Report) across its neuroscience and immunology portfolios. Biogencompetes with Lilly in Alzheimer’s disease through Leqembi, which it markets with Eisai. Like Lilly’s Kisunla, Leqembi targets amyloid beta, making BIIB/Eisai a direct competitor in the Alzheimer’s treatment market. Novartis competes with Lilly in both neuroscience and immunology. Its migraine drug Aimovig, marketed with Amgen, competes with Emgality, while Cosentyx competes with Taltz in psoriasis.
AbbVie also challenges Lilly across both therapeutic areas. Its migraine drug Qulipta competes with Emgality, while Skyrizi and Rinvoq compete with Omvoh in inflammatory bowel disease. Rinvoq also competes with Ebglyss in atopic dermatitis.
LLY’s Price Performance, Valuation and Estimates
Lilly stock has risen 19.3% so far this year compared with the industry’s growth of 17.4%. During the same period, the company has also outperformed the sector and the S&P 500, as seen in the chart below.
LLY Stock Price Movement
From a valuation standpoint, LLY stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 28.63 forward earnings, higher than 19.06 for the industry. However, the stock is trading below its five-year mean of 34.60.
LLY Stock Valuation
The Zacks Consensus Estimate for 2026 earnings per share has declined from $35.88 to $33.22 over the past 60 days, while that for 2027 has risen from $45.87 to $47.23.
LLY Estimate Movement
LLY has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.